alanine has been researched along with Aura in 31 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Merck Serono SA (formerly Serono), under license from Newron Pharmaceuticals SpA (following its acquisition of the rights from Pharmacia and Upjohn AB [now Pfizer Inc]), is developing the oral alpha-aminoamide derivative of milacemide, safinamide, a monoamine oxidase-B and glutamate release inhibitor, for the potential treatment of Parkinson's disease, epilepsy and restless legs syndrome." | 8.84 | Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome. ( Chazot, PL, 2007) |
| "Amino acid analysis of plasma and urine obtained from 12 patients with epilepsy indicated that the plasma concentrations of taurine and glutamic acid were much higher than might have been expected." | 7.65 | Biochemical observations following administration of taurine to patients with epilepsy. ( Anderman, F; Sacks, C; Sherwin, AL; Van Gelder, NM, 1975) |
| "Epilepsy is often considered to be a progressive neurological disease, and the nature of this progression remains unclear." | 5.72 | Insights into the development of pentylenetetrazole-induced epileptic seizures from dynamic metabolomic changes. ( Cheng, P; Jia, P; Liao, S; Meng, K; Xiao, C; Xu, R; Zhao, X; Zheng, X, 2022) |
| "Merck Serono SA (formerly Serono), under license from Newron Pharmaceuticals SpA (following its acquisition of the rights from Pharmacia and Upjohn AB [now Pfizer Inc]), is developing the oral alpha-aminoamide derivative of milacemide, safinamide, a monoamine oxidase-B and glutamate release inhibitor, for the potential treatment of Parkinson's disease, epilepsy and restless legs syndrome." | 4.84 | Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome. ( Chazot, PL, 2007) |
| "Safinamide (formerly PNU-151774E), a sodium and calcium channel modulator that also inhibits monoamine oxidase B (MAOB), is under development by Newron Pharmaceuticals for the potential treatment of epilepsy, Parkinson's disease (PD), pain and stroke [345222], [348351]." | 4.81 | Safinamide (Newron Pharmaceuticals). ( Chazot, PL, 2001) |
| "The association between the superoxide dismutase 2 (SOD2) Val16Ala polymorphism and the serum aminotransferase levels was retrospectively investigated in 207 valproic acid-treated patients with epilepsy." | 3.78 | Superoxide dismutase 2 Val16Ala polymorphism is a risk factor for the valproic acid-related elevation of serum aminotransferases. ( Deguchi, M; Ishitsu, T; Kaneko, S; Nakagawa, K; Noai, M; Ogusu, N; Oniki, K; Saruwatari, J; Yasui-Furukori, N; Yoshida, S; Yoshimori, Y, 2012) |
| "Amino acid analysis of plasma and urine obtained from 12 patients with epilepsy indicated that the plasma concentrations of taurine and glutamic acid were much higher than might have been expected." | 3.65 | Biochemical observations following administration of taurine to patients with epilepsy. ( Anderman, F; Sacks, C; Sherwin, AL; Van Gelder, NM, 1975) |
| " However, management of acute seizures in patients with COVID-19 as well as management of PWE and COVID-19 needs to consider potential drug-drug interactions between antiseizure drugs and candidate drugs currently assessed as therapeutic options for COVID-19." | 2.72 | Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications. ( Chandra, PP; Jain, S; Potschka, H; Tripathi, M; Vohora, D, 2021) |
| "Safinamide was originated by Farmitalia-CarloErba in Italy." | 2.42 | Safinamide: FCE 26743, NW 1015, PNU 151774, PNU 151774E. ( , 2004) |
| "Epilepsy is often considered to be a progressive neurological disease, and the nature of this progression remains unclear." | 1.72 | Insights into the development of pentylenetetrazole-induced epileptic seizures from dynamic metabolomic changes. ( Cheng, P; Jia, P; Liao, S; Meng, K; Xiao, C; Xu, R; Zhao, X; Zheng, X, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (48.39) | 18.7374 |
| 1990's | 4 (12.90) | 18.2507 |
| 2000's | 6 (19.35) | 29.6817 |
| 2010's | 3 (9.68) | 24.3611 |
| 2020's | 3 (9.68) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, X | 1 |
| Cheng, P | 1 |
| Xu, R | 1 |
| Meng, K | 1 |
| Liao, S | 1 |
| Jia, P | 1 |
| Zheng, X | 1 |
| Xiao, C | 1 |
| Iwahashi, Y | 1 |
| Toyama, Y | 1 |
| Imai, S | 1 |
| Itoh, H | 1 |
| Osawa, M | 1 |
| Inoue, M | 1 |
| Shimada, I | 1 |
| Jain, S | 1 |
| Potschka, H | 1 |
| Chandra, PP | 1 |
| Tripathi, M | 1 |
| Vohora, D | 1 |
| Vien, TN | 1 |
| Modgil, A | 1 |
| Abramian, AM | 1 |
| Jurd, R | 1 |
| Walker, J | 1 |
| Brandon, NJ | 1 |
| Terunuma, M | 1 |
| Rudolph, U | 1 |
| Maguire, J | 1 |
| Davies, PA | 1 |
| Moss, SJ | 1 |
| Maciejak, P | 1 |
| Szyndler, J | 1 |
| Turzyńska, D | 1 |
| Sobolewska, A | 1 |
| Taracha, E | 1 |
| Skórzewska, A | 1 |
| Lehner, M | 1 |
| Bidziński, A | 1 |
| Hamed, A | 1 |
| Wisłowska-Stanek, A | 1 |
| Płaźnik, A | 1 |
| Lewis, RW | 1 |
| Mabry, J | 1 |
| Polisar, JG | 1 |
| Eagen, KP | 1 |
| Ganem, B | 1 |
| Hess, GP | 1 |
| Saruwatari, J | 1 |
| Deguchi, M | 1 |
| Yoshimori, Y | 1 |
| Noai, M | 1 |
| Yoshida, S | 2 |
| Ogusu, N | 1 |
| Oniki, K | 1 |
| Yasui-Furukori, N | 1 |
| Kaneko, S | 1 |
| Ishitsu, T | 1 |
| Nakagawa, K | 1 |
| Fariello, RG | 2 |
| Chazot, PL | 2 |
| Sawa, M | 1 |
| Kaji, S | 1 |
| Izumi, T | 1 |
| Baba, M | 1 |
| Brandt, NJ | 1 |
| Christensen, E | 1 |
| Robitaille, Y | 1 |
| Sherwin, A | 1 |
| Bonhaus, DW | 1 |
| Lippincott, SE | 1 |
| Huxtable, RJ | 1 |
| van Gelder, NM | 4 |
| Janjua, NA | 1 |
| Metrakos, K | 1 |
| MacGibbon, B | 1 |
| Metrakos, JD | 1 |
| Abdul-Ghani, AS | 1 |
| Attwell, PJ | 1 |
| Singh Kent, N | 1 |
| Bradford, HF | 1 |
| Croucher, MJ | 1 |
| Jane, DE | 1 |
| Maj, R | 1 |
| Ukmar, G | 1 |
| Varasi, M | 1 |
| Pevarello, P | 1 |
| McArthur, RA | 1 |
| Salvati, P | 1 |
| Sakai, R | 1 |
| Koike, T | 1 |
| Sasaki, M | 1 |
| Shimamoto, K | 1 |
| Oiwa, C | 1 |
| Yano, A | 1 |
| Suzuki, K | 1 |
| Tachibana, K | 1 |
| Kamiya, H | 1 |
| Sherwin, AL | 2 |
| Sacks, C | 1 |
| Anderman, F | 1 |
| Schousboe, A | 1 |
| Westergaard, N | 1 |
| Sonnewald, U | 1 |
| Petersen, SB | 1 |
| Yu, AC | 1 |
| Hertz, L | 1 |
| Peeling, J | 1 |
| Sutherland, G | 1 |
| Schwartz, RM | 1 |
| Boyes, S | 1 |
| Aynsley-Green, A | 1 |
| Allen, IC | 1 |
| Grieve, A | 1 |
| Griffiths, R | 1 |
| Sills, MA | 1 |
| Forsythe, WI | 1 |
| Haidukewych, D | 1 |
| Craig, CR | 1 |
| Hartman, ER | 1 |
| Rasmussen, T | 1 |
| Courtois, A | 1 |
| Palo, J | 1 |
| Savolainen, H | 1 |
| Iivanainen, M | 1 |
| Kolpakov, VG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Taurine as an Anti-Manic Agent: A Double-Blind, Placebo-Controlled Study in Adolescents With Bipolar Disorder[NCT00391001] | Phase 1 | 4 participants (Actual) | Interventional | 2006-02-28 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for alanine and Aura
| Article | Year |
|---|---|
Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanize | 2021 |
Safinamide: FCE 26743, NW 1015, PNU 151774, PNU 151774E.
Topics: Alanine; Animals; Anticonvulsants; Antiparkinson Agents; Benzylamines; Clinical Trials, Phase I as T | 2004 |
Safinamide.
Topics: Alanine; Animals; Anticonvulsants; Benzylamines; Brain; Clinical Trials as Topic; Epilepsy; Humans; | 2007 |
Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome.
Topics: Alanine; Animals; Benzylamines; Clinical Trials as Topic; Epilepsy; Humans; Molecular Structure; Mon | 2007 |
Safinamide (Newron Pharmaceuticals).
Topics: Alanine; Animals; Anticonvulsants; Antiparkinson Agents; Benzylamines; Clinical Trials as Topic; Con | 2001 |
Regulatory role of astrocytes for neuronal biosynthesis and homeostasis of glutamate and GABA.
Topics: Alanine; Amino Acids; Animals; Astrocytes; Brain; Cell Communication; Epilepsy; gamma-Aminobutyric A | 1992 |
25 other studies available for alanine and Aura
| Article | Year |
|---|---|
Insights into the development of pentylenetetrazole-induced epileptic seizures from dynamic metabolomic changes.
Topics: Alanine; Animals; Anticonvulsants; Asparagine; Citrates; Creatine; Creatinine; Disease Models, Anima | 2022 |
Conformational equilibrium shift underlies altered K
Topics: Alanine; Ataxia; Bacterial Proteins; Epilepsy; Humans; Ion Channel Gating; Long QT Syndrome; Magneti | 2020 |
Compromising the phosphodependent regulation of the GABAAR β3 subunit reproduces the core phenotypes of autism spectrum disorders.
Topics: Alanine; Animals; Autism Spectrum Disorder; Behavior, Animal; Biotinylation; Cell Membrane; Dendriti | 2015 |
The effects of group III mGluR ligands on pentylenetetrazol-induced kindling of seizures and hippocampal amino acids concentration.
Topics: Alanine; Amino Acids; Aminobutyrates; Animals; Convulsants; Disease Models, Animal; Dose-Response Re | 2009 |
Dihydropyrimidinone positive modulation of delta-subunit-containing gamma-aminobutyric acid type A receptors, including an epilepsy-linked mutant variant.
Topics: Alanine; Allosteric Regulation; Cell Line; Drug Synergism; Epilepsy; Genetic Variation; Glutamic Aci | 2010 |
Superoxide dismutase 2 Val16Ala polymorphism is a risk factor for the valproic acid-related elevation of serum aminotransferases.
Topics: Adolescent; Adult; Aged; Alanine; Child; Child, Preschool; Epilepsy; Female; Humans; Infant; Male; M | 2012 |
[Effect of homopantothenic acid upon experimentally induced epileptiform waves].
Topics: Alanine; Aminobutyrates; Animals; Cats; Electroencephalography; Epilepsy; Penicillins; Strychnine | 1966 |
Omega-aminoaciduria induced by gamma-vinyl GABA.
Topics: Adult; Alanine; Aminocaproates; Aminoisobutyric Acids; beta-Alanine; Child; Epilepsy; Female; gamma- | 1984 |
gamma-vinyl GABA, and GABA and beta-alanine transamination.
Topics: 4-Aminobutyrate Transaminase; Alanine; Aminocaproates; beta-Alanine; Epilepsy; gamma-Aminobutyric Ac | 1984 |
High affinity (3H) beta-alanine uptake by scar margins of ferric chloride-induced epileptogenic foci in rat isocortex.
Topics: Alanine; Animals; Astrocytes; beta-Alanine; Cerebral Cortex; Chlorides; Epilepsy; Ferric Compounds; | 1984 |
Subcellular distribution of neuroactive amino acids in brains of genetically epileptic rats.
Topics: Alanine; Amino Acids; Animals; Brain Chemistry; Epilepsy; gamma-Aminobutyric Acid; Glutamates; Gluta | 1984 |
Plasma amino acids in 3/sec spike-wave epilepsy.
Topics: Adolescent; Adult; Alanine; Amino Acids; Aspartic Acid; Child; Child, Preschool; Epilepsy; Female; G | 1980 |
Anti-epileptogenic and anticonvulsant activity of L-2-amino-4-phosphonobutyrate, a presynaptic glutamate receptor agonist.
Topics: Alanine; Aminobutyrates; Amygdala; Analysis of Variance; Animals; Anticonvulsants; Calcium Radioisot | 1997 |
PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat.
Topics: Alanine; Animals; Anticonvulsants; Benzylamines; Diazepam; Epilepsy; Hippocampus; Kainic Acid; Lamot | 1998 |
Isolation, structure determination, and synthesis of neodysiherbaine A, a new excitatory amino acid from a marine sponge.
Topics: Alanine; Animals; Bridged Bicyclo Compounds, Heterocyclic; Convulsants; Dose-Response Relationship, | 2001 |
Biochemical observations following administration of taurine to patients with epilepsy.
Topics: Adolescent; Adult; Alanine; Anticonvulsants; Aspartic Acid; Cerebral Cortex; Child; Child, Preschool | 1975 |
High-resolution 1H NMR spectroscopy studies of extracts of human cerebral neoplasms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Amino Acids; Astrocytoma; Brain; Brain Neoplasm | 1992 |
Metabolic effects of three ketogenic diets in the treatment of severe epilepsy.
Topics: Adolescent; Adult; Alanine; Blood Glucose; Child; Child, Preschool; Dietary Fats; Energy Metabolism; | 1989 |
Differential changes in the content of amino acid neurotransmitters in discrete regions of the rat brain prior to the onset and during the course of homocysteine-induced seizures.
Topics: Alanine; Amino Acids; Animals; Aspartic Acid; Brain; Corpus Striatum; Epilepsy; gamma-Aminobutyric A | 1986 |
Role of octanoic and decanoic acids in the control of seizures.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adolescent; Alanine; Caprylates; Child; Child, Preschool; Circ | 1986 |
Concentration of amino acids in the brain of cobalt-epileptic rat.
Topics: Alanine; Amino Acids; Animals; Aspartic Acid; Brain Chemistry; Cerebral Cortex; Cobalt; Disease Mode | 1973 |
Amino acid content of epileptogenic human brain: focal versus surrounding regions.
Topics: Adolescent; Adult; Alanine; Amino Acids; Aminobutyrates; Aspartic Acid; Brain; Cerebral Cortex; Chil | 1972 |
Close correlation between changing content of specific amino acids in epileptogenic cortex of cats, and severity of epilepsy.
Topics: Alanine; Amino Acids; Aminobutyrates; Animals; Aspartic Acid; Cats; Cerebral Cortex; Cobalt; Electro | 1972 |
Free amino acids and carbohydrates in the cerebrospinal fluid of 305 mentally retarded patients: a screening study.
Topics: Adolescent; Adult; Alanine; Amino Acids; Arginine; Carbohydrates; Child; Child, Preschool; Chromatog | 1973 |
[On the probable pathogenetic mechanisms of epilepsy].
Topics: 5-Hydroxytryptophan; Alanine; Ammonia; Animals; Asparagine; Carboxy-Lyases; Epilepsy; Glutamates; Li | 1967 |